REGENXBIO Inc.
RGNX
$6.34
$0.213.43%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -92.82% | 43.00% | 22.88% | -4.20% | 469.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.82% | 43.00% | 22.88% | -4.20% | 469.79% |
| Cost of Revenue | 21.04% | 15.59% | -7.47% | 8.85% | -4.40% |
| Gross Profit | -290.90% | 0.79% | 24.70% | -16.68% | 174.68% |
| SG&A Expenses | 4.71% | 48.69% | 4.28% | 5.45% | 11.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 140.00% | -93.52% | 75.68% | 55.17% | 144.12% |
| Total Operating Expenses | 16.74% | 21.20% | -4.79% | 8.05% | -0.64% |
| Operating Income | -787.41% | -12.20% | 15.57% | -12.92% | 119.64% |
| Income Before Tax | -1,580.37% | -31.19% | -3.93% | -33.75% | 109.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,580.37% | -31.19% | -3.93% | -33.75% | 109.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,580.37% | -31.19% | -3.93% | -33.75% | 109.61% |
| EBIT | -787.41% | -12.20% | 15.57% | -12.92% | 119.64% |
| EBITDA | -594.37% | -13.56% | 16.50% | -14.21% | 127.93% |
| EPS Basic | -1,550.68% | -28.95% | -2.14% | -31.46% | 108.55% |
| Normalized Basic EPS | -1,550.68% | -28.94% | -2.15% | -31.46% | 108.84% |
| EPS Diluted | -1,552.70% | -28.95% | -2.14% | -31.46% | 108.55% |
| Normalized Diluted EPS | -1,552.64% | -28.94% | -2.15% | -31.46% | 108.83% |
| Average Basic Shares Outstanding | 2.08% | 1.73% | 1.75% | 1.74% | 12.31% |
| Average Diluted Shares Outstanding | 1.93% | 1.73% | 1.75% | 1.74% | 12.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |